PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/70, 9/20	A2	(11) International Publication Number: WO 00/38695
		(43) International Publication Date: 6 July 2000 (06.07.00)

(21) International Application Number: PCT/EP99/10155

(22) International Filing Date: 21 December 1999 (21.12.99)

(30) Priority Data:
9828620.6 23 December 1998 (23.12.98) GB

(71) Applicant *(for all designated States except US)*: GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: CHEEMA, Parbinder, Singh [GB/GB]; Glaxo Wellcome plc, Harmire Road, Barnard Castle, County Durham DL12 8DT (GB). GOWER, David [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). MOUNTER, Andrew, David [GB/GB]; Glaxo Wellcome plc, Harmire Road, Barnard Castle, County Durham DL12 8DT (GB). SABEY, Timothy, Giles [GB/GB]; Glaxo Wellcome plc, Harmire Road, Barnard Castle, County Durham DL12 8DT (GB).

(74) Agent: THORNLEY, Rachel, M.; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

This Sheet Has Been Replaced



(54) Title: ACICLOVIR COMPOSITIONS CONTAINING DIMETHICONE

(57) Abstract

There is provided an oil–in–water topical pharmaceutical formulation comprising a continuous aqueous phase comprising water, solubilised aciclovir and at least 30 % by weight of a water miscible polyhydric alcohol, with a dispersed oil phase and dimethicone.